Literature DB >> 20375234

Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study.

Olympia Zarkotou1, Spyros Pournaras, Evangelia Voulgari, Georgios Chrysos, Athanassios Prekates, Dionysios Voutsinas, Katerina Themeli-Digalaki, Athanassios Tsakris.   

Abstract

A matched 1:3 case-control study investigated factors predicting colistin-resistant versus colistin-susceptible KPC-producing Klebsiella pneumoniae acquisition and its impact on patient outcomes. Case patients were more often admitted from other institutions (P = 0.019) and had longer therapy with beta-lactam/beta-lactamase inhibitors (P = 0.002) and higher overall mortality (P = 0.05). All 52 study isolates were clonally related, suggesting horizontal dissemination. None of these parameters independently predicted colistin resistance, which probably occurred in a susceptible KPC-KP strain that was subsequently disseminated horizontally.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20375234      PMCID: PMC2884508          DOI: 10.1128/JCM.02301-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

Review 1.  Polymyxins revisited.

Authors:  David Landman; Claudiu Georgescu; Don Antonio Martin; John Quale
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

2.  Phenotypic detection of carbapenem-susceptible metallo-beta-lactamase-producing gram-negative bacilli in the clinical laboratory.

Authors:  Clare Franklin; Lisa Liolios; Anton Y Peleg
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

3.  CDC definitions for nosocomial infections, 1988.

Authors:  J S Garner; W R Jarvis; T G Emori; T C Horan; J M Hughes
Journal:  Am J Infect Control       Date:  1988-06       Impact factor: 2.918

4.  Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents.

Authors:  Simona Bratu; Pooja Tolaney; Usha Karumudi; John Quale; Mohamad Mooty; Satyen Nichani; David Landman
Journal:  J Antimicrob Chemother       Date:  2005-05-25       Impact factor: 5.790

5.  Ongoing epidemic of blaVIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey.

Authors:  M Psichogiou; P T Tassios; A Avlamis; I Stefanou; C Kosmidis; E Platsouka; O Paniara; A Xanthaki; M Toutouza; G L Daikos; L S Tzouvelekis
Journal:  J Antimicrob Chemother       Date:  2007-11-13       Impact factor: 5.790

6.  Evaluation of boronic acid disk tests for differentiating KPC-possessing Klebsiella pneumoniae isolates in the clinical laboratory.

Authors:  Athanassios Tsakris; Ioulia Kristo; Aggeliki Poulou; Katerina Themeli-Digalaki; Alexandros Ikonomidis; Dimitra Petropoulou; Spyros Pournaras; Danai Sofianou
Journal:  J Clin Microbiol       Date:  2008-12-10       Impact factor: 5.948

7.  Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.

Authors:  Mariana Castanheira; Hélio S Sader; Lalitagauri M Deshpande; Thomas R Fritsche; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

8.  Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.

Authors:  Leanne B Gasink; Paul H Edelstein; Ebbing Lautenbach; Marie Synnestvedt; Neil O Fishman
Journal:  Infect Control Hosp Epidemiol       Date:  2009-12       Impact factor: 3.254

9.  Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece).

Authors:  H C Maltezou; P Giakkoupi; A Maragos; M Bolikas; V Raftopoulos; H Papahatzaki; G Vrouhos; V Liakou; A C Vatopoulos
Journal:  J Infect       Date:  2009-02-26       Impact factor: 6.072

10.  Cluster of bloodstream infections caused by KPC-2 carbapenemase-producing Klebsiella pneumoniae in Manhattan.

Authors:  Abhijeet S Nadkarni; Tjark Schliep; Lamia Khan; Cosmina B Zeana
Journal:  Am J Infect Control       Date:  2009-03       Impact factor: 2.918

View more
  43 in total

1.  The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae.

Authors:  Meredith G Jernigan; Ellen G Press; M Hong Nguyen; Cornelius J Clancy; Ryan K Shields
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

2.  Colistin Resistance Caused by Inactivation of the MgrB Regulator Is Not Associated with Decreased Virulence of Sequence Type 258 KPC Carbapenemase-Producing Klebsiella pneumoniae.

Authors:  Fabio Arena; Lucia Henrici De Angelis; Antonio Cannatelli; Vincenzo Di Pilato; Marina Amorese; Marco Maria D'Andrea; Tommaso Giani; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

3.  Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.

Authors:  Andrea Endimiani; Kristine M Hujer; Andrea M Hujer; Mark E Pulse; William J Weiss; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2010-11-01       Impact factor: 5.191

4.  Outbreak of Klebsiella pneumoniae carbapenemase-2-producing K. pneumoniae sequence type 11 in Taiwan in 2011.

Authors:  Chun-Ming Lee; Chun-Hsing Liao; Wen-Sen Lee; Yung-Ching Liu; Jung-Jung Mu; Meng-Chih Lee; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

5.  Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients.

Authors:  C J Clancy; L Chen; R K Shields; Y Zhao; S Cheng; K D Chavda; B Hao; J H Hong; Y Doi; E J Kwak; F P Silveira; R Abdel-Massih; T Bogdanovich; A Humar; D S Perlin; B N Kreiswirth; M Hong Nguyen
Journal:  Am J Transplant       Date:  2013-09-06       Impact factor: 8.086

Review 6.  Clinical management of infections caused by multidrug-resistant Enterobacteriaceae.

Authors:  Mercedes Delgado-Valverde; Jesús Sojo-Dorado; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  Ther Adv Infect Dis       Date:  2013-04

7.  Detection of Klebsiella pneumoniae carbapenemase (KPC) production in non-Klebsiella pneumoniae Enterobacteriaceae isolates by use of the Phoenix, Vitek 2, and disk diffusion methods.

Authors:  Christopher D Doern; W Michael Dunne; Carey-Ann D Burnham
Journal:  J Clin Microbiol       Date:  2011-01-05       Impact factor: 5.948

Review 8.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

9.  A model for predicting nosocomial carbapenem-resistant Klebsiella pneumoniae infection.

Authors:  Duo Yang; Zeqiang Xie; Xuli Xin; Wenying Xue; Man Zhang
Journal:  Biomed Rep       Date:  2016-09-07

10.  Successful treatment of a disseminated infection with extensively drug-resistant Klebsiella pneumoniae in a liver transplant recipient with a fosfomycin-based multidrug regimen.

Authors:  J P Mills; M B Wilck; B C Weikert; P M Porrett; D Timko; K Alby; R A Bonomo; E A Blumberg
Journal:  Transpl Infect Dis       Date:  2016-09-07       Impact factor: 2.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.